PARP inhibitors (PARPis) are one of the most promising PARP-targeted drugs for some cancers, such as ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer (2–5). The gene discussed is PARP1; the disease is familial pancreatic carcinoma.